FDA Accepts Priority Review for Linvoseltamab to Treat Adult Patients With R/R MM

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

Related Keywords

Jo Panuwat ,Regeneron Pharmaceuticals ,Refractory Multiple Myeloma Accepted For ,Acceptance For Treatment ,Refractory Multiple ,Learn How Well Linvoseltamab Works Compared ,Adult Participants With ,Refractory Multiple Myeloma ,